Moby Intelligence

Wed, March 18, 2026 at 8:14 PM EDT 3 min read

• Management transitioned the company from a technology developer to a commercially driven 'gene editing engine' integrated into customer breeding programs.

• The value proposition has shifted to 'time-bound, predictable' trait development, returning edited elite germplasm to customers within 12 to 15 months.

• Performance in the rice (RISE) program is driven by seven customers representing a potential $200 million annual royalty opportunity across the Americas.

• The commercial model is evolving beyond single-trait licensing toward 'outsourced gene editing' services for entire partner portfolios in high-growth markets like India and Asia.

• Strategic positioning was validated by the UK government selecting Cibus as a technology partner for its farming innovation program.

• Management attributes recent momentum to a 'perfect storm' of technology readiness, operational scaling, and favorable regulatory shifts in the EU and UK.

• Operational efficiency improved through the consolidation of facilities and a shift toward semi-automated, robotic-assisted workflows.

• Initial market entry for herbicide-tolerant rice in Latin America is targeted for 2027, with U.S. expansion in 2028 and India/Asia entry by 2030.

• A definitive commercial agreement with Interoc is expected in late 2026 to support the 2027 launch in Ecuador and Colombia.

• The EU plenary session vote expected in late April 2026 serves as a major catalyst for opening 100 million acres of greenfield opportunity.

• Management expects to report Latin American field results and progress on chemistry registrations throughout the remainder of 2026.

• Financial guidance assumes a disciplined approach to capital, targeting an annual net cash usage of approximately $30 million or less in 2026.

• Completed the consolidation of the Oberlin facility into San Diego and wound down the Minnesota facility to streamline operations.

• Implemented workforce reductions and cost-saving initiatives that reduced 2025 operating expenses by approximately $10 million.

• Raised $22.3 million in gross proceeds in January 2026, extending the cash runway into late 2026.

• Recognized a $1.2 million increase in royalty liability interest expense compared to the prior year period.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.